You can contact MUFACE through the following contact form.
MUFACE anti-smoking programme
Since 1 January 2020, certain presentations of medicines for smoking cessation have been included in the financing of the National Health System (SNS). MUFACE finances all those medicines included in the SNS pharmaceutical delivery portfolio, under the conditions established by the Ministry of Health.
In June 2024, the Ministry of Health agreed on the funding of certain medicines for treatment in support of smoking cessation, in particular medicinal products containing BUPROPION, CYTISINE or CITISINICLINE and VARENICLINE subject to certain conditions. The funding of these drugs is restricted to patients who follow a smoking support or care program, with express motivation to stop smoking, who smoke 10 or more cigarettes a day and also have a high level of dependence qualified by the Fagerström test ≥ 7.
To have access to this therapy, a doctor’s prescription (prescription) is required.
Always in accordance with the provisions of the portfolio of services of the National Health System, MUFACE guarantees its mutualists the possibility of following an anti-smoking therapy when they meet the requirements for it, whether they have chosen Public Health Service or if their choice has been that of a concerted entity.
To establish a protocol of action in anti-smoking therapy for mutualists who have chosen concerted entities, a MUFACE’s Anti-Smoking Program . There are also other programs or protocols for certain groups, which are also available and valid. As indicated, to have access to this therapy a medical prescription (prescription) is needed. The user’s contribution will be 30%, as in any prescription of medicines.
Procedure for mutualists who have chosen the Public Health Service
The corresponding mutualist group of attachment to the Public Health Service (SPS) will follow the rules of inclusion in the program of these SPS.
The prescription will be made by electronic prescription, and no control by the Provincial Services of MUFACE is necessary.
Procedure for mutualists who have chosen a concerted entity
The mutualist group of attachment to an Insurance Institution must go to a Primary Care Doctor (MAP) who, after a first contact and assessment of certain characteristics that must be met, will determine their possible inclusion in the financing of the treatment of smoking cessation.
Once the MAP has decided to prescribe one of these drugs, the mutualist must go to their Provincial Service (SP) with the medical report or Model for the financing of anti-smoking drugs , and the official recipe of MUFACE.
Documentation of the programme for concerted entities
